All In Biotech

Free tool

FAERS Monitor: Xeloda

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020896 or its brand name (Xeloda, Capecitabine). Reports on generic versions are filed under their own applications.

Reports

91,426

Serious

75,506

83% of reports

Hospitalization

29,053

Death reported

18,299

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea13,713
  • death8,788
  • nausea8,520
  • palmar-plantar erythrodysaesthesia syndrome6,691
  • fatigue6,544
  • vomiting6,327
  • disease progression6,093
  • malignant neoplasm progression4,032
  • off label use3,895
  • asthenia3,441
  • decreased appetite3,305
  • neutropenia3,161
  • neuropathy peripheral2,944
  • dehydration2,742
  • dyspnoea2,690

Reports by year received

View as table
YearReports
2004642
2005823
2006959
20071,734
20082,153
20092,779
20102,889
20112,581
20125,959
20134,267
20143,115
20152,958
20162,929
20176,962
20184,771
20195,424
20206,546
20217,740
20227,175
20235,940
20245,255
20254,705
20263,120

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,962,733 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
palmar-plantar erythrodysaesthesia syndromeSignal6,69192.289.7430,799
disease progressionSignal6,09312.412.161,105
malignant neoplasm progressionSignal4,0329.49.129,161
neuropathy peripheralSignal2,9447.37.115,618
neutropeniaSignal3,1615.55.311,292
diarrhoeaSignal13,7135.04.943,928
dehydrationSignal2,7424.84.68,147
decreased appetiteSignal3,3053.33.25,298
vomitingSignal6,3273.13.19,220
nauseaSignal8,5202.52.47,826
deathSignal8,7882.42.37,111
astheniaSignal3,4412.12.02,041
fatigue6,5441.91.93,076
dyspnoea2,6901.11.122
off label use3,8951.01.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.